1. Fallowfield L. Evolution of breast cancer treatments: current options and quality-of-life considerations. Eur J Oncol Nursing 2004; 8: S37–82.
2. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001; 28: 291–304.
3. Brufman G, Biran S. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 1990; 29: 717–20.
4. Lundgren S, Gundersen S, Klepp R et al. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 1989; 14: 201–6.
5. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986; 46: 4823–6.
6. Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006–16.
7. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606.
8. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9.
9. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–9.
10. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
11. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
12. Boccardo F, Rubagotti A, Amoroso D et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treatment 2003; 82 (Suppl. 1), S6: abstr 3.
13. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88 (Suppl. 1), S7: abstr 2.
14. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol 2005; 23: 10s.
15. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793–802.
16. Goss PE. NCIC CTG MA.17 Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 2004; 22: 14S (abstr 847).
17. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
18. Coombes RC, Hall E, Snowdon CF, Bliss JM, on behalf of the Intergroup Exemestane Study (IES). The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen – updated survival analysis. Breast Cancer Res Treat 2004; 88 (Suppl. 1): S7.
19. Blamey RW. Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer 2002; 38: 615–34.
20. National Cancer Institute PDQ Statement. Breast Cancer (PDQ): Treatment. Stage IIIB, Inoperable IIIC, IV, Recurrent, and Metastatic Breast Cancer. National Cancer Institute, 2005.
21. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: breast cancer 2005. http://www.nccn.org.

М.М.Константинова1, Л.К.Овчинникова1, Н.Н.Ломакин2, М.Г.Галлеев3, Э.Ш.Неретина4, Г.З.Мухамедшина5, Ф.Х.Мухаметгалеева5

1 ГУЗ МООД МЗ МО, Балашиха;
2 Поликлиника ЦВКГ МВД, Москва;
3 РКОД, Уфа;
4 ГУЗ ООД, Курган;
5 РКОД, Казань